Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of AD-2101 and AD-2102 in Healthy Males
NCT04600284Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-2101 and AD-2102 in hypertension (HTN) (6 arms), sponsored by Addpharma, Inc. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Nov 2020; status: completed.
02
Drugs
AD-2101AD-2102
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04600284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600284.